<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04515576</url>
  </required_header>
  <id_info>
    <org_study_id>17530</org_study_id>
    <secondary_id>J1X-MC-GZHC</secondary_id>
    <nct_id>NCT04515576</nct_id>
  </id_info>
  <brief_title>A Study of LY3493269 in Participants With Type 2 Diabetes</brief_title>
  <official_title>Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple-Ascending Subcutaneous Doses of LY3493269 in Patients With Type 2 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this study is to determine the side effects related to LY3493269 in&#xD;
      participants with type 2 diabetes. Blood tests will be performed to check concentrations of&#xD;
      LY3493269 in the bloodstream. Each enrolled participant will receive LY3493269, dulaglutide,&#xD;
      or placebo. The study will last up to approximately 16 weeks for each participant and may&#xD;
      include up to 11 visits.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 25, 2020</start_date>
  <completion_date type="Actual">March 4, 2021</completion_date>
  <primary_completion_date type="Actual">March 4, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants with One or More Treatment-Emergent Adverse Event(s) (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration</measure>
    <time_frame>Baseline through final follow-up at Day 57</time_frame>
    <description>A summary of SAEs, TEAEs and other non-serious adverse events (AEs), regardless of causality, will be reported in the Reported Adverse Events module</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC) of LY3493269</measure>
    <time_frame>Baseline through final follow-up at Day 57</time_frame>
    <description>PK: AUC of LY3493269</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK: Maximum Concentration (Cmax) of LY3493269</measure>
    <time_frame>Baseline through final follow-up at Day 57</time_frame>
    <description>PK: Cmax of LY3493269</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics (PD):Change from baseline to Day 29 in Fasting Glucose (FG)</measure>
    <time_frame>Baseline, Day 29</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">56</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>LY3493269</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>LY3493269 administered Subcutaneous (SC).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dulaglutide</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Dulaglutide administered SC.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo administered SC.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY3493269</intervention_name>
    <description>Administered SC</description>
    <arm_group_label>LY3493269</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dulaglutide</intervention_name>
    <description>Administered SC</description>
    <arm_group_label>Dulaglutide</arm_group_label>
    <other_name>LY2189265</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Administered SC</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Are male or female not of childbearing potential&#xD;
&#xD;
          -  Have a body mass index of 23 to 50 kilograms per square meter (kg/mÂ²), inclusive, at&#xD;
             screening&#xD;
&#xD;
          -  Have had a stable body weight (&lt;5% body weight change) for the 3 months prior to&#xD;
             screening&#xD;
&#xD;
          -  Have not modified their diet or adopted any nutritional lifestyle modification in the&#xD;
             3 months prior to screening&#xD;
&#xD;
          -  Have type 2 diabetes mellitus (T2DM) controlled with diet and exercise alone or are on&#xD;
             a stable dose of metformin for at least 3 months before screening. Patients with&#xD;
             comorbid conditions commonly associated with diabetes (for example, hypertension,&#xD;
             hypercholesterolemia, hypothyroidism) may be eligible for inclusion if conditions are&#xD;
             assessed by the investigator to be well controlled and stable for at least 3 months&#xD;
             prior to screening&#xD;
&#xD;
          -  Have an HbA1c of at least 7.0% and no more than 10.5% at screening&#xD;
&#xD;
          -  Have clinical laboratory test results within the normal range for the population or&#xD;
             investigative site, or with abnormalities deemed not clinically significant by the&#xD;
             investigator&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Have type 1 diabetes mellitus or latent autoimmune diabetes in adults&#xD;
&#xD;
          -  Have uncontrolled diabetes, defined as an episode of ketoacidosis or hyperosmolar&#xD;
             state requiring hospitalization in the 6 months prior to screening&#xD;
&#xD;
          -  Have a history of proliferative diabetic retinopathy, diabetic maculopathy, or severe&#xD;
             nonproliferative diabetic retinopathy that requires acute treatment&#xD;
&#xD;
          -  Have had more than 1 episode of severe hypoglycemia, as defined by the American&#xD;
             Diabetes Association criteria, within 6 months before screening or has a history of&#xD;
             hypoglycemia unawareness or poor recognition of hypoglycemic symptoms.&#xD;
&#xD;
          -  Have a definitive diagnosis of autonomic neuropathy as evidenced by urinary retention,&#xD;
             resting tachycardia, orthostatic hypotension, or diabetic diarrhea&#xD;
&#xD;
          -  Have a history of acute or chronic pancreatitis&#xD;
&#xD;
          -  Have a self or family history (first-degree relative) of multiple endocrine neoplasia&#xD;
             type 2A or type 2B, thyroid C-cell hyperplasia, or medullary thyroid carcinoma&#xD;
&#xD;
          -  Have calcitonin levels of 20 picograms per millilitre (pg/mL) or more at screening&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Anaheim Clinical Trials, LLC</name>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <zip>92801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Miami Research Associates</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trials of Texas, Inc.</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://trials.lillytrialguide.com/en-US/trial/1xujziv0yfFVul40lqzrPv?conditionId=3bqjr5JHpKymwsYAWWaicU</url>
    <description>A Study of LY3493269 in Participants With Type 2 Diabetes</description>
  </link>
  <verification_date>March 15, 2021</verification_date>
  <study_first_submitted>August 14, 2020</study_first_submitted>
  <study_first_submitted_qc>August 14, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 17, 2020</study_first_posted>
  <last_update_submitted>March 19, 2021</last_update_submitted>
  <last_update_submitted_qc>March 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dulaglutide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

